Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of oral ICP-488 in cutaneous lupus erythematosus
ChiCTR2600121125Phase 2Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of icp-488 in discoid lupus erythematosus (DLE) and subacute cutaneous lupus erythematosus (SCLE) (3 arms), sponsored by Peking University First Hospital. Primary endpoint: Percentage change of CLASI-A relative to baseline at week 16. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
icp-488
03
Conditions
discoid lupus erythematosus (DLE)subacute cutaneous lupus erythematosus (SCLE)
Beyond the preview
Go deeper on ChiCTR2600121125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121125.